Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2

Purpose: The growth and survival of neurofibromatosis type 2 (NF2)–deficient cells are enhanced by the activation of multiple signaling pathways including ErbBs/IGF-1R/Met, PI3K/Akt, and Ras/Raf/Mek/Erk1/2. The chaperone protein HSP90 is essential for the stabilization of these signaling molecules. The aim of the study was to characterize the effect of HSP90 inhibition in various NF2-deficient models. Experimental Design: We tested efficacy of the small-molecule NXD30001, which has been shown to be a potent HSP90 inhibitor. The antiproliferative activity of NXD30001 was tested in NF2-deficient cell lines and in human primary schwannoma and meningioma cultures in vitro. The antitumor efficacy of HSP90 inhibition in vivo was verified in two allograft models and in one NF2 transgenic model. The underlying molecular alteration was further characterized by a global transcriptome approach. Results: NXD30001 induced degradation of client proteins in and suppressed proliferation of NF2-deficient cells. Differential expression analysis identified subsets of genes implicated in cell proliferation, cell survival, vascularization, and Schwann cell differentiation whose expression was altered by NXD30001 treatment. The results showed that NXD30001 in NF2-deficient schwannoma suppressed multiple pathways necessary for tumorigenesis. Conclusions: HSP90 inhibition showing significant antitumor activity against NF2-related tumor cells in vitro and in vivo represents a promising option for novel NF2 therapies. Clin Cancer Res; 19(14); 3856–70. ©2013 AACR.

[1]  R. Jain,et al.  Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism. , 2012, Neoplasia.

[2]  J. Slopis,et al.  Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways , 2011, Molecular Cancer Therapeutics.

[3]  M. Gerritsen,et al.  High-Content, High-Throughput Analysis of Cell Cycle Perturbations Induced by the HSP90 Inhibitor XL888 , 2011, PloS one.

[4]  O. Bruland,et al.  Global Gene Expression Profiling and Tissue Microarray Reveal Novel Candidate Genes and Down-Regulation of the Tumor Suppressor Gene CAV1 in Sporadic Vestibular Schwannomas , 2010, Neurosurgery.

[5]  Ivan Stamenkovic,et al.  Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. , 2010, Current protein & peptide science.

[6]  S. Rangaraju,et al.  Rapamycin Activates Autophagy and Improves Myelination in Explant Cultures from Neuropathic Mice , 2010, The Journal of Neuroscience.

[7]  R. Bronson,et al.  The Novel Hsp90 Inhibitor NXD30001 Induces Tumor Regression in a Genetically Engineered Mouse Model of Glioblastoma Multiforme , 2010, Molecular Cancer Therapeutics.

[8]  Jonathan A. Cooper,et al.  Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus , 2010, Cell.

[9]  P. Cayé-Thomasen,et al.  Deregulated Genes in Sporadic Vestibular Schwannomas , 2010, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[10]  M. Giovannini,et al.  Merlin / NF 2 Suppresses Tumorigenesis by Inhibiting the E 3 Ubiquitin Ligase CRL 4 DCAF 1 in the Nucleus , 2010 .

[11]  J. Golfinos,et al.  Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2 , 2009, Clinical Cancer Research.

[12]  A. Rubenstein,et al.  Synthesis of pochoxime prodrugs as potent HSP90 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[13]  T. Kiehl,et al.  Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). , 2009, Cancer research.

[14]  N. Socci,et al.  Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling , 2009, Molecular and Cellular Biology.

[15]  Sylwia Ammoun,et al.  Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. , 2008, Cancer research.

[16]  L. Neckers,et al.  Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor. , 2008, Angewandte Chemie.

[17]  Long-Sheng Chang,et al.  Phosphatidylinositol 3-Kinase/AKT Pathway Activation in Human Vestibular Schwannoma , 2008, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[18]  D. Scoles.  The merlin interacting proteins reveal multiple targets for NF2 therapy. , 2008, Biochimica et biophysica acta.

[19]  Aisha Siddiqa,et al.  Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways , 2008, BMC Cancer.

[20]  Yuval Kluger,et al.  High HSP90 expression is associated with decreased survival in breast cancer. , 2007, Cancer research.

[21]  I. Stamenkovic,et al.  Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin , 2007, Oncogene.

[22]  S. Carroll,et al.  Neuregulin Growth Factors and Their ErbB Receptors Form a Potential Signaling Network for Schwannoma Tumorigenesis , 2006, Journal of neuropathology and experimental neurology.

[23]  A. Nakashima,et al.  Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin. , 2006, Journal of biochemistry.

[24]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[25]  S. Ghatak,et al.  Hyaluronan Constitutively Regulates ErbB2 Phosphorylation and Signaling Complex Formation in Carcinoma Cells* , 2005, Journal of Biological Chemistry.

[26]  D. Evans,et al.  Incidence of Vestibular Schwannoma and Neurofibromatosis 2 in the North West of England over a 10-year Period: Higher Incidence than Previously Thought , 2005, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[27]  E. Sausville,et al.  Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models , 2005, Cancer Chemotherapy and Pharmacology.

[28]  D. Evans,et al.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. , 2004, American journal of human genetics.

[29]  W. Sessa,et al.  Regulation of survivin function by Hsp90 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[31]  A. Bretscher,et al.  ERM proteins and merlin: integrators at the cell cortex , 2002, Nature Reviews Molecular Cell Biology.

[32]  F. Linthicum,et al.  Immunohistochemistry study of human vestibular nerve schwannoma differentiation , 2002, Glia.

[33]  C. Hanemann,et al.  Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. , 2002, Human molecular genetics.

[34]  T. Jacks,et al.  The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. , 2001, Developmental cell.

[35]  C. Haipek,et al.  The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. , 2001, Genes & development.

[36]  N. Rosen,et al.  Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. , 2001, Cancer research.

[37]  N. Patronas,et al.  Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. , 2001, Radiology.

[38]  L. Neckers,et al.  Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex , 2000 .

[39]  A. Berns,et al.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. , 2000, Genes & development.

[40]  M. Wilm,et al.  Hsp90 is a core centrosomal component and is required at different stages of the centrosome cycle in Drosophila and vertebrates , 2000, The EMBO journal.

[41]  G. Thomas,et al.  Conditional biallelic Nf 2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2 , 2000 .

[42]  L. Neckers,et al.  Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. , 2000, Blood.

[43]  A. Berns,et al.  Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. , 1999, Genes & development.

[44]  T. Jacks,et al.  Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. , 1998, Genes & development.

[45]  P. Herrlich,et al.  CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene. , 1997, Cancer research.

[46]  S. Pulst,et al.  Neurofibromatosis 2 antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells. , 1996, Oncogene.

[47]  G. Rouleau,et al.  The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. , 1995, Cancer research.

[48]  R. Mirsky,et al.  The schwann cell precursor and its fate: A study of cell death and differentiation during gliogenesis in rat embryonic nerves , 1994, Neuron.

[49]  S. Pulst,et al.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 , 1993, Nature.

[50]  J. Haines,et al.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor , 1993, Cell.

[51]  K. Frazer,et al.  Epidemiology, pathogenesis, and genetics of acoustic tumors. , 1992, Otolaryngologic clinics of North America.